Generalized Anxiety and C-Reactive Protein Levels: A Prospective, Longitudinal Analysis

William E. Copeland, PhD\textsuperscript{a}, Lilly Shanahan, PhD\textsuperscript{b}, Carol Worthman, PhD\textsuperscript{c}, Adrian Angold, MRCPsych\textsuperscript{a}, and E. Jane Costello, PhD\textsuperscript{a}

\textsuperscript{a}Duke University Medical Center
\textsuperscript{b}University of North Carolina, Chapel Hill
\textsuperscript{c}Emory University

Abstract

Background—Generalized Anxiety Disorder (GAD) is highly comorbid with depression. Depression is associated with elevated levels of the inflammation marker C-reactive protein (CRP), cross-sectionally and over time. To date, no studies have looked at the association of CRP with GAD.

Methods—Ten waves of data from the prospective population-based Great Smoky Mountains Study (\(N = 1,420\)) were used, covering children in the community aged 9-16, 19, and 21 years old. Structured interviews were used at each assessment to assess GAD symptoms, diagnosis, and cumulative episodes. Bloodspots were collected and assayed for CRP levels.

Results—GAD was associated with increased levels of CRP in bivariate cross-sectional analyses. These bivariate associations, however, were attenuated after accounting for demographic, substance use, and health-related covariates. In longitudinal models, there was little evidence that CRP predicted later GAD. Associations from GAD to later CRP were attenuated in models adjusted for health-related covariates and there was evidence that the GAD-CRP association was mediated by BMI and medication use.

Conclusions—Similar to depression, GAD was associated with elevated levels of CRP, but the effect of GAD on CRP levels was explained by the effect of GAD on health-related behaviors such as BMI and medication use. This study suggests differences in the association between inflammation and depression and GAD.

Keywords

Inflammation; CRP; Generalized Anxiety Disorder; Epidemiology; Childhood; Adolescence

Introduction

Generalized anxiety disorder (GAD) is characterized by excessive or uncontrollable anxiety and worry, is associated with a range of physical symptoms (American Psychiatric Association, 1994), and is highly comorbid with depression at every stage of life (Angold et al., 1999a, Kessler et al., 2005) (Moffitt et al., 2007b). Several lines of empirical research...
have established that GAD and depression share many, although not all psychosocial and biological risk factors and correlates (American Psychiatric Association, 1994). Depression is associated with elevated levels of pro-inflammatory cytokines and the proteins released in response to increasing cytokine levels. The acute phase protein C-reactive protein (CRP) has been the focus of extensive epidemiologic investigation because of the association of elevated plasma CRP levels (>3 mg/L) with cardiovascular risk (The Emerging Risk Factors Collaboration, 2010, Shah et al., 2009) and aspects of metabolic syndrome (Tamakoshi et al., 2003, Pradhan et al., 2002, Ridker et al., 2003). Recent work on depression has identified robust cross-sectional and longitudinal associations with CRP (Howren et al., 2009, Copeland et al., 2012). Are such associations also observable between GAD and CRP?

Several previous findings suggest that such an association should be identified. First, family and twin studies have documented co-transmission of depression and GAD (Kendler et al., 1995, Eley and Stevenson, 1999, Thapar and McGuffin, 1997, Middeldorp et al., 2005) as well as strong bivariate genetic correlations between depression and GAD (Kendler et al., 2007, Kendler, 1996). Second, hypothalamic-pituitary adrenal axis and autonomic nervous system activity have both been implicated in depressive symptoms and CRP production (for reviews (Raison et al., 2006, Dantzer et al., 2008)); these systems are generally also activated in the context of anxiety (O’Donovan et al., 2010, Toker et al., 2005, Pitsavos et al., 2006), although few studies of physiological correlates have specifically focused on GAD. Third, depression and GAD tend to be responsive to the same active ingredients in drugs (Kuzma and Black, 2004). Finally, a number of studies comparing psychosocial correlates of depression and GAD have identified at least some similarities (Moffitt et al., 2007a).

Recent work has, however, also identified differences between depression and GAD, suggesting at least partially different etiological pathways. For example, divergence in correlates was found for a number of psychosocial adversities (Moffitt, 2007, Shanahan, 2008) and temperamental traits (Moffitt, 2007). Furthermore, a family history of depression was specifically associated with depression, but not with GAD (Moffitt, 2007; Shanahan, 2008), suggesting potential differences in at least some of the biological bases of these disorders.

The goal of this study was to test whether GAD would be associated with increased levels of the systemic inflammation marker CRP, both cross-sectionally and over time. It is also plausible, as was observed in part with depression (Copeland et al., 2012), that a portion of any identified association is accounted for by other health-related variables such as body-mass index, medication use, and smoking. Such an association would provide additional evidence for biological overlap between depression and GAD and provide some support for the combination of these disorders in DSM-5. A lack of association between GAD and CRP would implicate distinct biological processes in these otherwise closely-linked disorders.

### Methods and Materials

#### Participants

The Great Smoky Mountains Study is a longitudinal study of the development of psychiatric disorder and need for mental health services in rural and urban youth (Costello et al., 1996, Costello et al., 2003). A representative sample of three cohorts of children, age 9, 11, and 13 at intake, was recruited from 11 counties in western North Carolina using a multi-stage selection process. All children scoring above a predetermined cut-point (the top 25% of the total scores) on a screening questionnaire, plus a 1-in-10 random sample of the rest, were
recruited for detailed interviews. Of all subjects recruited, 80% (N=1420) agreed to participate.

Subjects were assessed annually to age 16 then again at ages 19 and 21. Participants were interviewed as closely as possible to their birthday each year. Across all waves, participation rates averaged 84% (range: 74-94%). About 8% of the area residents and the sample are African American, less than 1% are Hispanic, and 3% are American Indian.

**Procedures**

The parent (biological mother for 83% of interviews) and subject were interviewed by trained interviewers separately until the subject was 16, and subjects only thereafter. Before the interviews began, parent and child signed informed consent forms approved by the Duke University Medical Center Institutional Review Board. Each parent and child received an honorarium for their participation.

Using a previously described procedure (Worthman and Stallings, 1997), blood samples were obtained at the beginning of each in-person assessment, as follows: two finger-prick samples (yielding 10 spots total per visit) were collected at a 20-minute intervals, applied to standardized collection paper, immediately refrigerated upon drying, and express shipped (without refrigeration) to the laboratory within two weeks of collection. Samples were then stored at −28°C until they were assayed. This protocol is consistent with the rigorous quality control program developed for newborn screening programs (Mei et al., 2001) and has been used in a number of epidemiologic studies involving blood spot CRP measures (McDade et al., 2006, Williams and McDade, 2009).

**Assessment**

*Generalized Anxiety* is characterized by excessive anxiety and worry that a person finds difficult to control, and is associated with a range of physical symptoms (restlessness, easily fatigues, difficulty concentrating, irritability, muscle tension, and sleep disturbance) (American Psychiatric Association, 1994). Generalized anxiety disorder variables were assessed using the *Child and Adolescent Psychiatric Assessment* until age 16, and its upward extension, the *Young Adult Psychiatric Assessment* thereafter (Angold and Costello, 2000, Angold et al., 1999b). These structured interviews were coded by a trained interviewer and each interview was then checked by a supervisor. The time frame for determining the presence of most behaviors was the past three months to minimize forgetting and recall biases, although onset dates were also collected for all symptoms. A symptom was counted as present if reported by either parent or child or both, as is standard in clinical practice. Scoring programs written in SAS by the senior authors combined information about the date of onset, duration, and intensity of each symptom to create GAD diagnoses according to the fourth edition of the Diagnostic and Statistical Manual of the American Psychiatric Association (American Psychiatric Association, 1994). Two-week test-retest reliability of diagnoses is comparable to that of other highly-structured child psychiatric interviews (Angold and Costello, 1995). Construct validity as judged by 10 different criteria including comparison to other interviews and ability to predict mental health service use is good to excellent (Angold and Costello, 2000). Generalized anxiety disorder status was measured by two variables: Current generalized anxiety disorder (binary) and the number of total generalized anxiety symptoms (range: 0-6). Cumulative generalized anxiety exposure was assessed by looking at the total number of GAD episodes reported up until the current assessment (range: 0-3). This variable was included because of the evidence that cumulative depressive episodes predicted later CRP levels and other studies linking perturbations in inflammation levels to repeated psychological distress (Danese et al., 2008, Copeland et al., 2012).
C-Reactive Protein—Our assay for CRP in whole-blood spots was a biotin-Streptavidin based immunofluorometric system improving on a previously published method (McDade et al., 2004). One assay was completed for each subject at each observation. Streptavidin A-coated microtiter plates bind a biotinylated capture antibody to CRP, clone C2. A second Europium-labeled antibody then binds to the Streptavidin A Biotin-C2-CRP complex; fluorescence of the resultant complex is directly proportional to the CRP concentration in each well. Minimum detectable dose for the assay is .010 mg/L. For low, medium, high, and very high controls (.022, .259, 1.208, and 3.271 mg/L, respectively), within-assay coefficient of variation (CV)(precision) is 2.0%, 1.2%, 1.6%, and 1.4%, respectively, while between-assay CV (reliability) runs 14.4%, 13.9%, 12.3% and 10.9%, respectively. CRP remains stable in dried blood spots for at least 5 days at room temperature or 14 days at 4 °C, and stable for years at −26 °C.

A validation study was performed with matched serum and blood spot samples assayed for CRP (n=38). As has been reported for many other analytes including CRP (Worthman and Stallings, 1997, McDade et al., 1997, McDade et al., 2004), a close linear correlation was identified between serum and blood spot CRP values (n=29; $R^2 = .98$, $p<.0001$). Serum equivalents therefore were calculated using the following algorithm based on the serum-blood spot regression: serum (hsCRP) = 1.38*(Blood Spot CRP Value) – 0.97. Blood spot CRP measures have been used in a number of epidemiologic studies (Williams and McDade, 2009, McDade et al., 2006, McDade et al., 2005). Observations with values above 10 mg/L indicate frank infection and were removed from statistical analysis (N=190 from a total of 6000 observations), whereas values below 10 mg/L the extent of chronic low grade systemic inflammation associated with cardiovascular and metabolic risk (Pearson et al., 2003).

Covariates included variables typically associated with variation in CRP levels (Woodward et al., 2003, Elovainio et al., 2006) or used as covariates in studies of CRP and depression (Gimeno et al., 2009, Stewart et al., 2009, Janicki Deverts et al., 2010, Matthews et al., 2010). These included age, sex, race, BMI, medication use, substance use, low SES, and recent physical ailments. BMI was calculated from weight and height measurements completed at each assessment. For all assessments completed before subjects were 20, BMI values were corrected for age and sex (Ogden et al., 2002). The substance use assessment of the CAPA and YAPA interviews assesses current nicotine, alcohol, and illicit drug use. Dichotomous variables were included to indicate recent use of these substances. A physical health problems survey adapted from Form HIS-1A (1998), US Department of Commerce for the U.S. Public Health Service was administered to assess 39 common ailments (e.g., diabetes, anemia, mononucleosis). A binary variable indicating any health ailments within the last 12 months was used for all analyses. Analyses were also tested using the following separate health categories: atopic (e.g., food/digestive allergy, asthma, and, respiratory allergy), injuries, infections (tonsilitis, ear infection, frequent diarrhea or colitis, and urinary tract infections) and chronic diseases (e.g., diabetes, epilepsy, cancer and chronic heart disease). Medication use within the prior year was also assessed from the Child and Adolescent Services Assessment (Ascher et al., 1996), which focuses on psychotropic medications, but also assessed prescribed medications not related to psychiatric problems. All analyses were tested using a broad-based medication use variables as well as categories for individual medication groups (e.g., antidepressant, stimulant, and other prescribed medications). Low SES coded whether the subject’s family displayed any 2 of the following 3 indicators: income below the federal poverty line, low parental education attainment, and low parental occupation status. Additional physiological covariates evaluated alongside CRP in older samples at risk for cardiovascular problems (e.g., blood pressure, lipids, or insulin) were not assessed.
Analytic framework

All subjects were assigned a weight inversely proportional to their probability of selection, so that the results are representative of the population from which the sample was drawn and not biased from the oversampling procedure. CRP values were positively skewed and were log10-transformed after scaling for non-negative values by adding 1. Models predicting GAD symptoms or cumulative GAD episodes employed Poisson regression, models predicting diagnostic status employed logistic regression and those predicting CRP employed linear regression. All associations were tested using weighted regression models in a generalized estimating equations framework implemented by SAS PROC GENMOD. For all analyses, multiple observations were used for each subject and robust variance (sandwich type) estimates adjusted the standard errors of the parameter estimates for the repeated observations. The covariance matrix was specified as autoregressive in all analyses.

All longitudinal models used values from the prior assessment to predict current levels of the outcome variable. As such, only subjects with multiple assessments were included and subjects with more than two assessments contributed multiple observations. For example, if a subject had 5 assessments, then they contributed 4 observations to the current analyses (wave 1 predicting wave 2, wave 2 predicting wave 3, wave 3 predicting wave 4, and wave 4 predicting wave 5).

Missing data

By age 21, 8806 total assessments had been completed. Of these, bloodspots were obtained for 6087 (69.1%). Bloodspots were not available either because the subject refused or because the interviews were completed by phone. For in-person interviews, 79.4% of subjects agreed to provide bloodspots. Comparisons of observations in which blood spots were collected to those in which the subjects refused indicated no significant differences on any of the GAD outcomes. Of the 6087 bloodspots collected, 6000 (98.6%) were successfully assayed for CRP (190 were removed due to elevated CRP levels indicating infection). Of the 1420 study participants, 1,334 (93.9%) provided blood spot samples assayed for CRP in one year or more. The median number of CRP samples provided was 5 (mean =4.77 (SD=2.24); range =1-9).

Results

Sample characteristics

Table 1 shows the characteristics of the full analytic sample in person-observations (5810 observations of 1334 subjects). GAD-related outcomes were significantly associated with sex, age, BMI, tobacco use, alcohol use, illicit drug use, medication use, and current health ailments. CRP was associated with age, BMI, tobacco use, alcohol use, other drug use, medication use, current health ailments and low SES. This pattern of findings suggests that all covariates merit inclusion.

The overlap between GAD and depression variables was high. Thirty-nine-point-nine percent of those meeting criteria for GAD also met criteria for a depressive disorder (OR=40.9; 95%CI =18.0-92.9, p <0.0001). There was similarly high overlap between symptoms (r = 0.72, p < 0.0001) and cumulative episodes to date (r = 0.55, p < 0.0001). If CRP is associated with GAD, it is reasonable to ask if such associations are independent of depression.

Cross-sectional Associations

A series of regression models tested the cross-sectional associations between CRP and all GAD-related outcomes (table 2). For each outcome, a simple bivariate model was tested as
well as a model adjusting for covariates. There was strong evidence of association between
CRP and GAD-related outcomes in bivariate models. All associations were attenuated to
nonsignificance by the inclusion of health-related covariates. BMI and medication use were
significant predictors in all models predicting CRP.

Longitudinal Associations

Longitudinal bi-directional associations were tested in a series of similar models similar to
those for the cross-sectional associations (table 3). The simple longitudinal model predicted
the outcome using the predictor and prior status on the outcome variable (e.g., prior CRP
and GAD symptoms predicting current GAD symptoms). As such, this model predicts
change in the outcome variable across assessments. There was little evidence of either CRP
predicting later GAD-related outcomes or vice versa in the simple models. The lone
exception was GAD symptoms predicting later CRP levels adjusting for prior CRP. This
association, like other marginal associations, was attenuated after accounting for current
health-related covariates. The models testing effects of GAD-related variables on later CRP
levels implicated a common set of covariates which included race, time since the last
interview, BMI, nicotine use, and current medication use.

These concurrent covariates may mediate or account for the association between past GAD
symptoms and current CRP as has been observed, in part, for depression (Copeland et al.,
2012). Each significant covariate was tested as a potential mediator using a multistage
regression approach (Baron and Kenny, 1986, MacKinnon et al., 2002). Identification of
potential mediators required the following: 1) GAD symptoms were associated with the
covariate (table 4, column 1); 2) In models controlling for the GAD symptoms, the covariate
was associated with CRP (column 2); 3) In models controlling for the covariate, the
association between the GAD symptoms and CRP was either no longer statistically
significant or was attenuated (column 3); and 4) A statistically significant indirect path
existed between the GAD symptoms and CRP through the covariate, as measured by the
Sobel test (Sobel, 1982) (column 4). Neither race nor time since last interview were
associated with the GAD symptoms and, thus, were not included in table 3. Both BMI and
medication mediated the association from prior GAD symptoms to current CRP.

Followup analyses

CRP levels greater than > 3 mg/L indicate increased risk for cardiovascular disease in adults
(Pearson et al., 2003). There was no evidence that changes to the definition of CRP, either
by dichotomizing CRP levels at CRP > 3 mg/L or by including cases with CRP > 10 mg/L
(which is indicative of acute infection) affected the results of either the cross-sectional or
longitudinal analysis. It is plausible that the association of CRP with GAD differs is found in
some subgroups but not in others. To test for this pattern, interaction terms were entered into
each of the simple/bivariate between the predictor and each demographic variable (sex and
race) or significant covariate. Significant interactions occurred at the rate expected by
chance and were no more likely to include one demographic variable or covariate than
another. Finally, it is possible - albeit unlikely - that it is the portion of GAD that is
independent of depression that is associated with CRP levels. All analyses were rerun
including depression variables as covariates. As expected, this did not change the pattern of
associations.

Discussion

GAD is highly comorbid with depression (Moffitt et al., 2007b), and depression is both
directly and indirectly associated with elevated levels of CRP (Howren et al., 2009). On this
basis, we predicted that GAD would also be associated with elevated levels of CRP. There
was evidence supporting this hypothesis in bivariate associations both cross-sectionally and over time. These associations attenuated, however, with the inclusion of health-related covariates and both BMI and medication use which mediated the longitudinal associations between GAD variables and later CRP levels. Thus, GAD does affect levels of CRP, but this effect is accounted for by the effect GAD on health-related behaviors. The direct association with elevated low-grade inflammation is an area of divergence between GAD and depression for the age-groups examined here.

Despite the extensive literature on the depression-CRP link, only few studies have looked at the association between CRP and any measure of anxiety. The ATTICA study examined concurrent associations between State-Trait Anxiety Inventory scores and a number of markers of immunity/inflammation including hsCRP in a sample of 853 adults (Pitsavos et al., 2006). They found a small, but significant, association (rho=0.18) that persisted after controlling for relevant covariates. A case-control study of 27 anxious patients and 29 nonanxious controls found no association between CRP levels and anxiety as measured by a self-report questionnaire (O’Donovan et al., 2010). Finally, a test of the CRP-anxiety association in a large sample of employees completing a routine health exam at an Israeli medical center found no association (Toker et al., 2005). These studies suggest a consensus for little evidence of association between CRP with anxiety. In our study which employed structured interviews to assess GAD, the aspect of anxiety most closely tied to depression, there was no independent association.

If indeed depression, but not GAD, is associated with CRP directly, what does this specificity suggest? Although the areas of overlap between GAD and depression are legion (Moffitt et al., 2007b, Watson, 2005), divergence in biological correlates may reinforce the notion that these disorders have at least partially distinct neurobiological profiles. There is also evidence that GAD and depression are preceded by somewhat different profiles of psychosocial risk factors (Moffitt et al., 2007a). The study of biological correlates has generally been limited to markers of HPA axis function. Here again, results have been mixed with some studies showing increased levels of basal and peak salivary cortisol levels (Mantella et al., 2008) and other studies failing to find any association of GAD with diurnal cortisol levels (Hoehn-Saric et al., 1991). Similar mixed results have been reported regarding nonsuppression of cortisol in response to the dexamethasone suppression test (Schweizer et al., 1986, Tiller et al., 1988). Studies of HPA-related indicators and depression, however, have been plagued by similar inconsistencies (Kaufman et al., 2001). One general conclusion from the literature is that disorder-biological correlate associations still tend to be small, affected by a range of health-related behaviors, and often limited to specific subgroups (by age, number of disorder episodes). Thus, while our findings are consistent with a conceptualization of GAD and depression as closely-linked entities with distinct biological correlates, more work needs to be done on the conditions under which such associations are detectable for all psychiatric disorders.

Bivariate associations between GAD and CRP seem to be attenuated by a broad set of health-related variables including substance use, body-mass index, medication use. A similar set of variables attenuated the associations of depression-related variables on later CRP levels (albeit not to the point of nonsignificance for cumulative depressive episodes). Analyses testing bivariate associations ignore the normative clustering of these multiple health-risk behaviors and the elevated levels of CRP. Although the influence of any single risk factor may be important in terms of understanding the pathophysiology of mild inflammation, these risk factors are much difficult to tease apart in the real world. Risk reduction strategies may opt to use this normative clustering to identify subjects at highest risk for elevated inflammation patterns rather than focusing on individual risk factors.
Limitations
The Great Smoky Mountains study has several strengths besides its longitudinal, prospective design: A population-based design that minimized selection biases; anxiety variables assessed repeatedly with structured interviews that allowed us to look at various aspects of anxiety; repeated collection of bloodspots that allowed for subjects to provide up to 9 values of CRP across 12 years; and assessment of a wide range of domains that allowed us to control for covariates of anxiety and CRP. But the sample is not representative of the U.S. population (Native Americans overrepresented and African Americans and Latinos under-represented).

The criteria for GAD may change in DSM-5. The primary proposed changes for DSM-5 GAD include removing criterion B (difficulty controlling worry), reducing the threshold for criterion C (associated symptoms), and adding a behavioral avoidance criterion (DSM-5 Anxiety Disorders Work Group, 2010). The first change is only meant to remove a redundancy and the reduced threshold for criterion C already applies in children (Andrews et al., 2010). The primary change then, as it relates to the current study, is the additional of the behavioral avoidance criterion. One goal of this addition is indeed to increase differentiation with other anxiety and mood disorders (Andrews et al., 2010). While this new criterion is only propositional, this change, if adopted, may affect the association of GAD with CRP.

Conclusion
Our study provides little support for a robust association between GAD and CRP. Instead, significant cross-sectional or longitudinal associations were entirely attenuated by a cluster of health-related covariates known to predict both CRP and anxiety. In the case of depression, there is evidence for an independent effect of recurrent depressive episodes on later CRP levels (Copeland et al., 2012), but this was not the case for GAD. This suggests caution in interpretation of the recent evidence of overlap between GAD and depression in developmental course and lifetime comorbidity. Despite general similarities, it has not been demonstrated that depression and GAD share biological correlates related either to HPA-axis function or CRP levels. These differences may prove instructive in understanding the specificity of associations between negative emotions and inflammation.

Acknowledgments
The work presented here was supported by the National Institute of Mental Health (MH63970, MH63671, MH48085), the National Institute on Drug Abuse (DA/MH11301), NARSAD (Early Career Award to First Author), and the William T Grant Foundation.

The work presented here was supported by the National Institute of Mental Health (MH080230, MH63970, MH63671, MH48085), the National Institute on Drug Abuse (DA/MH11301), NARSAD (Early Career Award to First Author), and the William T Grant Foundation.

References


ANGOLD, A.; COX, A.; PRENDERGAST, M.; RUTTER, M.; SIMONOFF, E.; COSTELLO, EJ.; ASCHER, BH. The Young Adult Psychiatric Assessment (YAPA). Duke University Medical Center; Durham, NC: 1999b.


Psychol Med. Author manuscript; available in PMC 2012 December 01.


Psychol Med. Author manuscript; available in PMC 2012 December 01.


Psychol Med. Author manuscript; available in PMC 2012 December 01.

Table 1

Descriptive information and concurrent associations between primary variables and covariates

<table>
<thead>
<tr>
<th></th>
<th>Total sample (N=5810)</th>
<th>GAD sx.</th>
<th>GAD dx.</th>
<th>Cumulative episode</th>
<th>CRP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean GAD sx.</td>
<td>0.38 (0.76)</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>GAD dx.</td>
<td>2.2% (146)</td>
<td>7.73 (5.48-10.91)</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Mean cumulative episodes</td>
<td>0.08 (0.31)</td>
<td>2.45 (2.03-2.97)</td>
<td>51.36 (18.19-145.0)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Mean CRP levels (mg/L)</td>
<td>1.04 (2.02)</td>
<td>1.50 (1.11-2.02)</td>
<td>2.53 (1.00-6.39)</td>
<td>3.18 (1.87-5.41)</td>
<td>--</td>
</tr>
<tr>
<td><strong>Covariates</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex (% female)</td>
<td>48.7% (2766)</td>
<td>1.26 (1.00-1.59)</td>
<td>2.02 (1.04-3.92)</td>
<td>1.63 (0.88-3.01)</td>
<td>1.02 (0.99-1.05)</td>
</tr>
<tr>
<td>Mean age</td>
<td>14.21 (3.19)</td>
<td>1.03 (1.01-1.06)</td>
<td>1.12 (1.03-1.22)</td>
<td>1.18 (1.13-1.25)</td>
<td>1.02 (1.01-1.02)</td>
</tr>
<tr>
<td>Race (% White)</td>
<td>89.7% (3905)</td>
<td>0.86 (0.71-1.05)</td>
<td>0.69 (0.39-1.21)</td>
<td>0.75 (0.45-1.28)</td>
<td>1.14 (1.12-1.17)</td>
</tr>
<tr>
<td>Mean BMI</td>
<td>22.37 (5.62)</td>
<td>1.01 (1.00-1.03)</td>
<td>1.03 (1.00-1.06)</td>
<td>1.08 (1.05-1.11)</td>
<td>1.02 (1.02-1.02)</td>
</tr>
<tr>
<td>Alcohol use</td>
<td>12.8% (850)</td>
<td>1.40 (1.13-1.75)</td>
<td>2.44 (1.16-5.12)</td>
<td>2.24 (1.57-3.19)</td>
<td>1.08 (1.05-1.11)</td>
</tr>
<tr>
<td>Tobacco use</td>
<td>13.5% (1143)</td>
<td>1.41 (1.11-1.78)</td>
<td>2.86 (1.43-5.74)</td>
<td>2.41 (1.61-3.60)</td>
<td>1.11 (1.08-1.15)</td>
</tr>
<tr>
<td>Other drug use</td>
<td>8.1% (571)</td>
<td>1.50 (1.11-2.03)</td>
<td>3.17 (1.32-7.60)</td>
<td>1.97 (1.27-3.05)</td>
<td>1.07 (1.03-1.11)</td>
</tr>
<tr>
<td>Medication use</td>
<td>30.2% (1842)</td>
<td>1.75 (1.46-2.09)</td>
<td>2.00 (1.13-3.54)</td>
<td>1.48 (0.93-2.37)</td>
<td>1.06 (1.04-1.09)</td>
</tr>
<tr>
<td>Recent health ailments</td>
<td>34.7% (2013)</td>
<td>1.61 (1.37-1.91)</td>
<td>1.97 (1.16-3.34)</td>
<td>1.55 (1.23-1.95)</td>
<td>1.05 (1.03-1.08)</td>
</tr>
<tr>
<td>Low SES</td>
<td>20.1% (1607)</td>
<td>1.18 (0.98-1.42)</td>
<td>1.22 (0.65-2.28)</td>
<td>1.44 (0.96-2.16)</td>
<td>1.05 (1.02-1.07)</td>
</tr>
</tbody>
</table>

Means and standard deviations are reported for continuous variables and percentages and sample sizes are included for dichotomous variables. Reported CRP mean and standard deviation values are from untransformed variables. All associations between CRP and other variables use log10-transformed values. Associations of primary variable with other variables were tested with either linear regression, Poisson, or logistic regression. CRP=C-Reactive Protein; BMI = Body-mass index; SES= socioeconomic status.
### Table 2

Cross-sectional associations between CRP and generalized anxiety

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Outcome</th>
<th>Effect of predictor</th>
<th>Bivariate</th>
<th>B (SE)</th>
<th>p</th>
<th>Adjusted for covariates</th>
<th>B (SE)</th>
<th>p</th>
<th>Significant Covariates</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP</td>
<td>GAD sx.&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.38 (0.16)</td>
<td>0.01</td>
<td>0.17 (0.18)</td>
<td>0.33</td>
<td>2, 9, 10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP</td>
<td>GAD dx.&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.90 (0.48)</td>
<td>0.06</td>
<td>0.50 (0.59)</td>
<td>0.40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP</td>
<td>Cumulative episode&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.97 (0.31)</td>
<td>0.002</td>
<td>0.23 (0.21)</td>
<td>0.28</td>
<td>1, 2, 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAD sx.</td>
<td>CRP&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.02 (0.007)</td>
<td>0.02</td>
<td>0.007 (0.007)</td>
<td>0.33</td>
<td>2, 5, 9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAD dx.</td>
<td>CRP&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.06 (0.04)</td>
<td>0.14</td>
<td>0.03 (0.04)</td>
<td>0.43</td>
<td>2, 5, 6, 9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cumulative episodes</td>
<td>CRP&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.07 (0.03)</td>
<td>0.02</td>
<td>0.004 (0.02)</td>
<td>0.85</td>
<td>2, 5, 6, 9</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Models were tested with either linear<sup>a</sup>, Poisson<sup>b</sup>, or logistic<sup>c</sup> regression. Covariates include the following: 1= sex; 2= race; 3=age; 5=BMI; 6=current nicotine use; 7 = current alcohol use; 8= current illicit drug use; 9 = current medication use; 10= recent health ailments; 11= current low SES. CRP=C-Reactive Protein; BMI = Body-mass index; SES= socioeconomic status.
Table 3

Bidirectional longitudinal associations between CRP and generalized anxiety

<table>
<thead>
<tr>
<th>Predictor status at preceding assessment</th>
<th>Outcome</th>
<th>Effect of prior predictor</th>
<th>Significant Covariates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Simple (B (SE), p)</td>
<td>Adjusted for covariates (B (SE), p)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4, 9, 10</td>
</tr>
<tr>
<td>CRP</td>
<td>GAD sx. (^b)</td>
<td>0.17 (0.25) 0.49</td>
<td>0.17 (0.24) 0.48</td>
</tr>
<tr>
<td>CRP</td>
<td>GAD dx. (^c)</td>
<td>0.35 (0.61) 0.56</td>
<td>0.06 (0.61) 0.92</td>
</tr>
<tr>
<td>CRP</td>
<td>Cumulative episodes (^d)</td>
<td>0.64 (0.34) 0.06</td>
<td>0.12 (0.25) 0.64</td>
</tr>
<tr>
<td>GAD sx.</td>
<td>CRP(^a)</td>
<td>0.03 (0.009) 0.007</td>
<td>0.02 (0.01) 0.09</td>
</tr>
<tr>
<td>GAD dx.</td>
<td>CRP(^a)</td>
<td>0.06 (0.04) 0.12</td>
<td>0.03 (0.03) 0.33</td>
</tr>
<tr>
<td>Cumulative episodes</td>
<td>CRP(^a)</td>
<td>0.05 (0.03) 0.09</td>
<td>0.02 (0.03) 0.37</td>
</tr>
</tbody>
</table>

Models were tested with either linear\(^a\), Poisson\(^b\), or logistic\(^c\) regression. Simple models include prior status on the outcome variable. Covariates include the following: 1 = sex; 2 = race; 3 = age; 4 = time since last interview; 5 = BMI; 6 = current nicotine use; 7 = current alcohol use; 8 = current illicit drug use; 9 = current medication use; 10 = recent health ailments; 11 = current low SES. CRP = C-Reactive Protein; BMI = Body-mass index; SES = socioeconomic status. Sx = symptoms; Dx = diagnoses.
Table 4

Tests of potential mediators of the association between GAD symptoms and later CRP

<table>
<thead>
<tr>
<th></th>
<th>1. GAD symptoms to mediator</th>
<th>2. Mediator to CRP</th>
<th>3. GAD symptoms to CRP</th>
<th>4. Sobel test</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B (SE)</td>
<td>B (SE)</td>
<td>B (SE)</td>
<td>p</td>
</tr>
<tr>
<td>BMI</td>
<td>0.54 (0.18), p&lt;0.01</td>
<td>0.01 (0.001), p&lt;0.001</td>
<td>0.02 (0.009), p=0.07</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Nicotine Use</td>
<td>0.26 (0.07), p&lt;0.001</td>
<td>0.04 (0.02), p&lt;0.05</td>
<td>0.02 (0.009), p&lt;0.05</td>
<td>0.08</td>
</tr>
<tr>
<td>Medication Use</td>
<td>0.25 (0.06), p&lt;0.001</td>
<td>0.04 (0.01), p&lt;0.001</td>
<td>0.02 (0.009), p&lt;0.05</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Models were tested with either Poisson\(^a\) or logistic\(^b\) regression. Columns numbered 2 and 3 provide results from models in which both GAD symptoms variable and potential mediator predicted current CRP status. Models adjusted for demographic covariates and prior CRP status. Sobel test assess significance of indirect pathway. CRP=C-Reactive Protein; BMI = Body-mass index. Sx = symptoms.